WHO Monitors New ‘Sigma’ Variant as Winter Cases Spike

Health officials report a sharp increase in respiratory infections across the Northern Hemisphere, driven by the emergence of the highly transmissible Sigma sub-variant of COVID-19.

As the 2025 winter season intensifies, the World Health Organization (WHO) has officially classified the SARS-CoV-2 sub-lineage Sigma (HV.4) as a “Variant of Interest.” Epidemiological data released this week indicates that this new strain is responsible for nearly 40% of new infections in Europe and North America, prompting renewed calls for vulnerable populations to update their vaccination status. While hospitalizations have seen a modest uptick, experts emphasize that the situation remains distinct from the pandemic phases of the early 2020s, with healthcare systems currently managing the load without the need for restrictive social measures.

Characteristics of the Sigma Variant

Virologists at the Centers for Disease Control and Prevention (CDC) note that the Sigma variant possesses a unique spike protein mutation that allows it to bypass some existing immunity derived from previous infections. However, clinical evidence suggests that while the variant is more contagious, it does not cause more severe disease in healthy adults. The primary symptoms reported—severe fatigue, sore throat, and upper respiratory congestion—align with previous Omicron lineages, though the duration of symptoms appears to be slightly prolonged.

Seasonal Endemic Phase

Public health strategists are characterizing the current surge as a typical manifestation of the virus’s transition to an endemic seasonal pattern, similar to influenza. Dr. Elena Rossi, a leading immunologist at the European Medicines Agency, stated that “COVID-19 has synchronized with the winter viral season.” Consequently, many nations have integrated COVID-19 boosters into their annual flu shot campaigns. Pharmacies in London, New York, and Berlin are reporting steady demand for the updated bivalent vaccines released in October 2025, which were tweaked to target lineages closely related to Sigma.

No Return to Lockdowns

Despite the rise in case numbers, government officials have firmly ruled out a return to lockdowns or mandatory business closures. The focus has shifted entirely to “personal risk management.” Authorities in Germany and France have issued recommendations for mask-wearing in crowded public transport and nursing homes but have stopped short of mandates. The economic consensus is that the global market cannot sustain further disruptions, and the current level of population immunity is sufficient to prevent a collapse of critical infrastructure.

Long COVID Focus

With acute mortality rates remaining low, the scientific community is redirecting resources toward understanding and treating “Long COVID.” The 2025 surge has renewed concerns about post-viral syndromes, as a small percentage of even mild Sigma cases result in lingering cognitive or physical symptoms. Major research grants have been announced in the United States and United Kingdom this month to accelerate clinical trials for therapeutics specifically designed to clear viral reservoirs and reduce chronic inflammation in affected patients.